Antibodies to glycans dominate the host response to schistosome larvae and eggs: Is their role protective or subversive? by Eberl, M. et al.
1238
Antibodies to Glycans Dominate the Host Response to Schistosome Larvae
and Eggs: Is Their Role Protective or Subversive?
Matthias Eberl,1 Jan A. M. Langermans,2
Richard A. Vervenne,2 A. Kwame Nyame,3
Richard D. Cummings,3 Alan W. Thomas,2
Patricia S. Coulson,1 and R. Alan Wilson1
1Department of Biology, University of York, York, United Kingdom;
2Department of Parasitology, Biomedical Primate Research
Centre, Rijswijk, The Netherlands; 3Department of Biochemistry
and Molecular Biology, Oklahoma Center for Medical
Glycobiology, University of Oklahoma Health
Sciences Center, Oklahoma City
Multiple exposures of chimpanzees to the radiation-attenuated schistosome vaccine provoked
a strong parasite-specific cellular and humoral immune response. Specific IgM and IgG were
directed mainly against glycans on antigens released by cercariae; these were also cross-reactive
with soluble antigens from larvae, adult worms, and eggs. Egg deposition was the major antigenic
stimulus after challenge of vaccinated and control chimpanzees with normal parasites, eliciting
strong antiglycan responses to egg secretions. Glycan epitopes recognized included LacdiNAc,
fucosylated LacdiNAc, LewisX (weakly), and those on keyhole limpet hemocyanin. Antibodies
to peptide epitopes became prominent only during the chronic phase of infection, as glycan-
specific IgM and IgG decreased. Because of their intensity and cross-reactivity, the antiglycan
responses resulting from infection could be a smoke screen to subvert the immune system away
from more vulnerable larval peptide epitopes. Their occurrence in humans might explain the
long time required for antischistosome immunity to build up after infection.
Epidemiologic studies show that schistosome infection in-
tensities among persons living in endemic areas are not nec-
essarily correlated with the pattern of contact with contami-
nated water [1, 2] but rather are influenced by the presence of
natural resistance or acquired immunity [3–5]. Antibody pro-
duction is a prominent feature of the immune response in pa-
tients with schistosomiasis, and particular isotypes correlate
with resistance or susceptibility to infection [6–11]. A substan-
tial proportion of the antibodies detected in patients with acute
or chronic infections is directed against carbohydrate epitopes,
many shared among larval, worm, and egg glycoproteins [12–
14], and some cross-react with glycans of keyhole limpet he-
mocyanin (KLHg) [15, 16]. Levels of KLHg-reactive IgM and
IgG antibody are high at the acute and low at the chronic stage
of the infection, permitting diagnostic discrimination between
the 2 patient groups [17, 18]. However, the overall importance
of glycan-specific antibodies to protection or pathology is still
not clear, and only a relatively modest amount of information
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is available [19, 20] about specific structures or expression of
relevant glycan antigens. Thus, better analysis of the differential
recognition of antigenic glycoconjugates and proteins is re-
quired for comprehension of the immune response in human
schistosomiasis.
Studies of infected humans provide only cross-sectional data,
because of the ethical requirement to give chemotherapy on di-
agnosis. This precludes a longitudinal examination of the im-
mune response through acute to chronic infection, which can be
done only in laboratory animals. In primate models, protective
immunity against challenge infection with Schistosoma mansoni
is at least partially dependent on an efficient humoral immune
response. Thus, protection in baboons and vervets multiply ex-
posed to the radiation-attenuated (RA) vaccine, the most effec-
tive schistosome vaccine available to date, correlates well with
the levels of parasite-specific IgG antibodies [21–23]. These find-
ings in primates are corroborated by experiments showing that
a degree of protective immunity can be passively transferred to
naive recipient mice by serum from multiply vaccinated donor
mice [24]. Analysis of the reactivity to glycoconjugates in mice
shows that the RA vaccine induces lower titers of anticarbohy-
drate antibodies than does a patent schistosome infection [13,
25]. Moreover, anti-KLHg antibodies from a rabbit do not confer
passive protection on mice [26]. However, in primates no infor-
mation is available about the recognition pattern of periodate-
sensitive glycan epitopes and periodate-resistant peptide epitopes
after vaccination or infection.
We recently investigated the efficacy of the RA vaccine in the
chimpanzee, the host genetically and physiologically closest to
humans. Multiply vaccinated chimpanzees developed a strong
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parasite-specific cellular and humoral immune response and were
partially protected against subsequent challenge with S. mansoni,
as judged by an amelioration of the acute disease and the overall
morbidity and a 40% reduction in egg output compared with
control chimpanzees (M.E., J.A.M.L., P. A. Frost, et al., un-
published data). Here we examined the reactivity of carbohydrate
and peptide epitopes with antibodies from vaccinated and in-
fected chimpanzees. Our findings provide a basis for understand-
ing the development of the immune response to S. mansoni over
the time from infection to chronic disease.
Materials and Methods
Hosts and parasites. This study was carried out in 6 unrelated,
healthy 5–6-year-old male chimpanzees (Pan troglodytes) selected
from the colony housed at the Biomedical Primate Research Centre
(BPRC; Rijswijk, The Netherlands). The whole experimental sys-
tem was validated at the BPRC by a successful vaccination/chal-
lenge study in C57Bl/6 mice (data not shown). In brief, 3 chim-
panzees were exposed 3 times to 9000 attenuated S. mansoni
cercariae (300 Gy g-radiation from a 60Co source at the BPRC) on
shaved abdominal skin at 5-week intervals. Three weeks after the
last exposure, the 3 vaccinated chimpanzees and 3 naive control
chimpanzees were challenged percutaneously with 2000 normal
(i.e., nonattenuated) cercariae. At the end of this study, at time
points between postchallenge (PC) weeks 28 and 36, by clinical
evaluation, all chimpanzees were cured with praziquantel (Droncit;
Bayer). After being shown to be egg negative, each was retired
within the BPRC facilities.
Antigen preparations. Soluble adult worm antigen preparation
(SWAP), soluble lung-stage antigen preparation (SLAP), freshly
transformed schistosomula (known as 0–3-h released antigen prep-
aration [0–3-hRAP]), soluble egg antigens (SEAs), and egg-secreted
proteins (ESPs) were formulated, as described elsewhere [27, 28].
Recombinant SmE16 [29] was purified by using Talon affinity ma-
trix (Clontech Laboratories) [30]. Bovine serum albumin (BSA)–
conjugated lacto-N-neotetraose (LNnT-BSA), LacdiNAc tetraose
(LDNT-BSA), and LacdiNAc fucopentaose (LDNFP-BSA) were
synthesized as before [31]. BSA-conjugated lacto-N-fucopentaose
III (LNFPIII-BSA) was purchased from V-Labs and KLH from
Sigma.
Antibody levels. Serum samples were prepared from aliquots
of peripheral blood taken from each chimpanzee at 1–3-week in-
tervals and were stored at 80C until further use. IgG and IgM
antibodies against various schistosome antigen preparations were
determined by ELISA, and the following coating concentrations
and serum dilutions were determined to be optimum for the antigen
preparations used (data not shown): SWAP and SLAP, 2.5 mg/mL
(1:1500); 0–3-hRAP, 0.2 mg/mL (1:20,000); SEAs, 0.5 mg/mL (1:
20,000); ESPs, 0.1 mg/mL (1:20,000); SmE16, 0.2 mg/mL (1:500);
KLH, 0.25 mg/mL (1:1500); LNnT-BSA, LDNT-BSA, and
LDNFP-BSA, 2.5 mg/mL (1:1500); LNFPIII-BSA, 2.5 mg/mL (1:
500). The plates were probed with alkaline phosphatase–labeled
goat anti-human IgG or IgM (Biosource), both diluted 1:5000, and
developed with BluePhos Microwell substrate solution (Kirkegaard
& Perry Laboratories). Absorbance was quantified at 630 nm with
an ELISA reader (Dynatech MR500); data shown in the figures
represent raw optical density (OD) values.
To remove periodate-resistant carbohydrate epitopes [32], the
plates were coated overnight with antigens as described above,
washed twice with 0.1 M sodium acetate (pH 4.5), and incubated
at 37C for 1 h with 20 mM sodium m-periodate (Sigma) dissolved
in 0.1 M sodium acetate or with 0.1 M sodium acetate only as a
control. After 2 washes with sodium acetate and one with PBS,
the plates were treated with 50 mM sodium borohydride (Sigma)
in PBS. The reaction was stopped after 30 min at room temperature
by 5 washes with 10 mM Tris/HCl (pH 8.0), 150 mM NaCl, and
0.05% Tween-20. Subsequently, the routine ELISA protocol was
applied.
Results
Antibody response to stage specifically released antigens.
Antigens released by invading schistosome larvae or by eggs
deposited in the host tissue are likely to interact directly with
the immune system and provoke a detectable response. There-
fore, we investigated the reactivity of serum samples from vac-
cinated and challenge control chimpanzees against antigen ei-
ther released by freshly transformed schistosomula (0–3-hRAP)
or secreted by cultured eggs (ESPs). For comparison, we tested
the commonly used crude antigen preparations, SLAP, SWAP,
and SEAs.
In the vaccinated group, SLAP-specific IgM was present at
the first sampling time point 3.5 weeks after the first immuni-
zation. The level increased with each vaccination and peaked at
the time of challenge infection, then dropped rapidly (figure 1A).
A small secondary peak at about PC week 6 represented a mem-
ory response triggered by worm maturation and the onset of egg
laying, as it coincided with the development not only of high
SLAP- but also of high SWAP- and SEA-specific IgM levels in
the challenge control group (data not shown). In the controls,
the antibody response to SLAP was not evident before PC week
5 and peaked at PC weeks 8–10, with maximum levels identical
to those in the vaccinated animals. In both groups, the IgM levels
gradually returned to near baseline by PC week 36. The initial
IgG response followed the time course observed for IgM but
with a slight delay (figure 1B). In the vaccinated group, repeated
exposure to attenuated parasites boosted the IgG titers, which
peaked by PC week 1 and had a secondary increase from week
PC 6 onward. Control animals produced detectable SLAP-spe-
cific IgG, starting at PC week 6, until they reached a stable
maximum. During the chronic disease phase, the IgG levels in
the 2 groups were indistinguishable.
ESP-reactive IgM and IgG were already detectable after vac-
cination and reached maximum levels about the time of chal-
lenge (similar to the SLAP-driven response). This suggests that
previous exposure to the RA vaccine induced antibodies cross-
reactive with various parasite stages, including eggs, before
challenge (figure 1C, 1D). However, unlike the response to
SLAP, a stronger IgM response to ESPs was seen in the controls
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Figure 1. Levels of schistosome-specific antibodies, shown as mean optical densities (ODs) and SEM of 3 chimpanzees for IgM (A, C, and
E) and IgG (B, D, and F) antibodies against soluble lung-stage antigen preparation (SLAP) (A and B), egg-secreted proteins (ESPs) (C and
D), and 0–3-h released antigen preparation (0–3-hRAP) (E and F). , Control group; , vaccinated group.
than in the vaccinated chimpanzees. Moreover, both groups
produced much higher amounts of IgG (OD, 0.8–1.0) than of
IgM (OD, 0.1–0.2) specific for ESPs than for SLAP (OD,
0.6–0.7 vs. 0.6).
Analysis of larval secretions revealed that the vaccinated
chimpanzees exhibited lower 0–3-hRAP–specific IgM levels
than did the controls, similar to findings for ESPs (figure 1E).
Also, the initial pattern of primary and secondary IgG re-
sponses against 0–3-hRAP in the vaccinated group was the
same as for SLAP and ESPs (figure 1F). However, in striking
contrast to all other antigens tested, which showed stable IgG
levels throughout the chronic disease (figure 1B, 1D; data not
shown), the 0–3-hRAP–specific IgG levels dropped after PC
weeks 15–20 and were at baseline levels by PC week 36. Sim-
ilarly, 0–3-hRAP–specific IgG in the control group developed
analogously to SLAP and ESPs but declined rapidly after
reaching a maximum level at PC week 12.
Dependence of antibody cross-reactivity after vaccination on
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Figure 2. Levels of schistosome-specific antibodies before and after removal of carbohydrate epitopes. Data are representative optical densities
from 1 vaccinated chimpanzee (V2) for IgG antibodies against periodate-treated keyhole limpet hemocyanin (KLH) (A), Schistosoma mansoni
egg–specific calcium-binding protein (SmE16) (B), soluble adult worm antigen preparation (SWAP) (C), soluble egg antigens (SEAs) (D), egg-
secreted proteins (ESPs) (E), and 0–3-h released antigen preparation (0–3-hRAP) (F). Results from other vaccinated animals were similar (data
not shown). , Antigens incubated in buffer only; , antigens treated with periodate.
antigen glycosylation. Because of the cross-reactivity of anti-
bodies with egg and larval antigens, we examined in more detail
the importance of protein glycosylation in the development of
the immune response after vaccination and subsequent infec-
tion. This was done with serum from only 1 vaccinated chim-
panzee (V2) due to limitations of material, but data from rep-
resentative time points for the other vaccinated animals were
similar (data not shown). IgG antibodies reactive with KLHg
were induced shortly after exposure to attenuated cercariae (fig-
ure 2A) but declined after PC week 12. Not surprisingly, the
anti-KLHg IgG reactivity was abrogated by previous treatment
of the antigen with sodium periodate. In contrast, recognition
of the egg-specific calcium-binding protein SmE16 was not in-
fluenced by periodate oxidation of the antigen (figure 2B; i.e.,
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Figure 3. Levels (optical ) of antibodies recognizing periodate-resistant peptide epitopes during chronic infection of 3 individualdensities SEM
chimpanzees, namely, IgG antibodies against soluble adult worm antigen preparation (SWAP) (A), soluble egg antigens (SEAs) (B), egg-secreted
proteins (ESPs) (C), and Schistosoma mansoni egg–specific calcium-binding protein (SmE16) (D). For better comparisons between groups, naive
values for controls are shown at week 13 (before vaccination) and at postchallenge week 0. Hatched bars, control group; filled bars, vaccinated
group.
treatment did not modify peptide epitopes). IgG antibodies
against SWAP, SEAs, and ESPs produced before challenge
largely bound to periodate-sensitive epitopes, whereas reactivity
against periodate-resistant epitopes built up later in the course
of the infection (figure 2C–2E). Of importance, treatment with
periodate abrogated the reaction with 0–3-hRAP (figure 2F),
thus revealing a close parallel with KLHg. The discrepancy
between intact and periodate-treated antigen preparations re-
vealed a gradation in the reactivity attributable to glycans (0–3-
hRAP 1SEAs 1SWAP 1ESPs). For all antigens tested, levels
of protein-specific IgM antibodies were very low under the as-
say conditions used (data not shown).
Antibody response to periodate-resistant peptide epitopes dur-
ing chronic infection. For investigation of the protein-specific
antibody response after challenge, all antigens were treated with
periodate (after doubling the coating concentrations to increase
the signal in this particular experiment). A significant periodate-
resistant antibody response to various antigen preparations de-
veloped between PC weeks 7 and 17, somewhat earlier and
slower for SWAP (figure 3A), and later but steeper for SEAs
(figure 3B) and ESPs (figure 3C). In contrast, in all 6 chim-
panzees, recognition of KLHg and 0–3-hRAP was completely
abrogated by prior treatment with periodate (data not shown;
figure 2). At the chronic stage of the infection, SEA-specific
antibody levels and, less noticeably, SWAP- and ESP-specific
levels were higher in the control chimpanzees; this was mirrored
by a similar difference in the SmE16-specific response between
the groups (figure 3D).
Antibody response to defined carbohydrate epitopes. Since the
antibody response after vaccination was mainly directed against
periodate-sensitive structures, we further analyzed the involve-
ment of several known glycan epitopes and compared the data
with the reaction against the heterogeneous glycans of KLH.
Multiple vaccinations induced a stronger anti-KLHg IgG re-
sponse than that induced by a normal schistosome infection (data
not shown) but a weaker IgM response (figure 4A). In both cases,
the antibody titers did not remain stable over the course of the
disease and gradually declined from maximum levels. In both
groups, we detected IgM antibodies specific for LDN (figure 4B)
and LDNF (figure 4C) and, to a lesser extent, LNFPIII, which
contains the Lewis X (LeX) epitope (figure 4D). A control glycan
(LNnT) was not recognized by any serum (data not shown). In
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Figure 4. Carbohydrate-specific IgM levels (mean optical ) of 3 individual chimpanzees for antibodies against keyhole limpetdensities SEM
hemocyanin (KLH) (A), LacdiNAc (LDN) (B), fucosylated LacdiNAc (LDNF) (C), and Lewis X (LeX) (D). , Control group; , vaccinated
group.
the vaccinated chimpanzees, LDN- and LDNF-driven IgM
peaked at the time of challenge, rose after PC week 4 to a sec-
ondary maximum, and slowly decayed. However, in 1 vaccinated
chimpanzee (V3), IgM levels stayed elevated until PC week 36
(data not shown). In the control group, LDN- and LDNF-spe-
cific IgM increased at the same time as the secondary response
in the vaccinated group and peaked between PC weeks 7 and
17. The antibody titers were elevated longer than was observed
for anti-KLHg IgM and did not wane as rapidly as with KLHg.
By PC week 36, a substantial reactivity against LDN and LDNF
was still present in 2 control serum samples (C2, C3; data not
shown). Of importance, for all 3 glycans tested (LDN, LDNF,
and LeX), peak antibody levels in the control group were higher
than those in the vaccinated chimpanzees.
Surprisingly, the IgG response against these glycans was
much more variable within the 2 groups than that for IgM
(figure 5). Only some chimpanzees mounted significant re-
sponses of LDN- (V2; C1, C2) and LDNF-specific IgG (V1,
V2; C2, C3), respectively, despite similar IgG levels against
KLHg. Levels of LeX-specific IgG were generally insignificant,
with a marginal increase in C1 (data not shown). In all cases,
the IgG levels increased after PC week 6 and were negligible
in the vaccinated chimpanzees before challenge infection.
Discussion
Our longitudinal study of more than 1 year’s duration of
chimpanzees exposed to schistosomes is unique in charting the
evolution of antibody responses through acute and chronic
phases of the disease. We examined the effects both of vacci-
nation with attenuated cercariae and of challenge infection with
normal cercariae by using the conventional soluble antigenic
preparations, SLAP, SWAP, and SEAs. In addition, we ex-
ploited 2 further preparations, both produced by parasite stages
during normal biologic processes. The antigens in 0–3-hRAP
are released by cercariae, primarily from acetabular glands,
during penetration of the host’s skin [33]; ESP antigens are
released by viable mature eggs and are thought to be involved
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Figure 5. Levels of carbohydrate-specific IgG, shown as optical densities for antibodies against keyhole limpet hemocyanin (), LacdiNAc
(), and fucosylated LacdiNAc (H17009) in 6 individual chimpanzees. V1, V2, and V3, vaccinated group; C1, C2, and C3, control group.
in their interactions with gut and liver tissues [28]. Larval se-
cretions should provide more meaningful provocations of the
immune response with respect to protection than do the somatic
antigens released when attenuated larvae die (i.e., SLAP); simi-
larly, ESPs may be more relevant to the induction of granu-
lomatous pathology than are the somatic constituents of the
egg (e.g., SEAs). It must be emphasized that the mammalian
host will be exposed to much smaller amounts of secreted larval
antigens during the infection process than of secreted egg anti-
gens after patency. Indeed, it is possible to dissect the antibody
responses to larval secretions only by giving the host a signifi-
cant dose of attenuated larvae that cannot mature.
Multiple exposures of the 3 test chimpanzees to irradiated
cercariae (cumulatively 27,000) elicited potent IgM and IgG
responses to both 0–3-hRAP and SLAP that peaked at the time
of challenge. Not surprisingly, in view of the small antigenic
input, 2000 normal parasites provoked little primary antibody
in the challenge controls or even a secondary response in vac-
cinated animals. The start of egg deposition was the major
antigenic event that induced and sustained antibody production
in both groups of animals. Probing of antibody responses after
vaccination with the various antigens revealed considerable
cross-reactivity between the larval preparations and SWAP,
SEAs, and ESPs. It is very unlikely that this was due to break-
through of vaccinating parasites, since eggs were not detected
in the feces before PC weeks 5–6, nor were IgG antibodies
detected against the stage-specific egg antigen SmE16 in serum
before PC weeks 6–7. Moreover, levels of circulating anodic
antigen were not elevated before challenge (G. J. van Dam,
personal communication).
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Virtually the entire vaccine-induced antibody was directed at
periodate-sensitive glycan epitopes, regardless of the prepara-
tion, suggesting common glycosylation motifs shared between
disparate proteins in the various life cycle stages. Cross-reac-
tivity of egg glycan epitopes and the surface of newly trans-
formed schistosomula with antibodies from chronically infected
mice has been reported [12]. The early antibodies elicited by
egg deposition in the chimpanzees were also predominantly
directed against glycan epitopes, and levels of antibodies rec-
ognizing periodate-resistant and presumably peptide-specific
epitopes became marked only as the infection progressed from
the acute to the chronic phase. The significance to protective
immunity of the strong antiglycan responses to larvae, the shar-
ing of epitopes between larvae and eggs, and the boosting of
those responses by egg deposition is unclear. Indeed, the anti-
glycan responses might collectively be interpreted as a smoke
screen to divert the immune system; this would mask vulnerable
peptide epitopes or larva-specific glycan epitopes that could
mediate a protective response. Support for the immune sub-
version hypothesis is provided by the lack of evidence from
animal experiments that schistosome eggs, used as immuno-
gens, can protect rodents or primates against challenge [34–36].
Also, if the very slow buildup of antipeptide responses in chim-
panzees also occurs in humans, it could partly explain the long
time required for protective immunity to develop after a natural
schistosome infection [37, 38]. Clearly, further studies are re-
quired to establish the importance of antiglycan versus anti-
peptide responses to protective immunity.
The 40% protection elicited in chimpanzees by the RA vac-
cine deserves comment. The nature of the protective mechanism
appears to differ in rodents and primates, the former being
protected by a single vaccination whereas the latter require3
exposures [39]. There is a much higher parasite load relative to
body mass in the rodent host, and there may also be differences
in immune priming due to variations in the migration pattern
of larvae [39, 40]. The outcome in the mouse is a strong type
1 cell-mediated immunity that is responsible for the bulk of
protection and is associated with low antibody levels largely
reactive with peptide epitopes [13]. In the chimpanzee, type 2
cell-mediated responses are prominent at the time of challenge,
implicating antibody in the effector mechanism (M.E.,
J.A.M.L., P. A. Frost, et al., unpublished data). Thus, protec-
tion may be mediated either by the low levels of antipeptide
antibody achieved by 3 vaccinations or by larva-specific non–
cross-reacting glycan responses. Indeed, one effect of irradia-
tion might be to modify glycan expression by attenuated larvae
[41], thereby diminishing the smoke screen and facilitating an-
tipeptide immunity. However, this hypothesis needs to be vali-
dated by using known larval or worm recombinant proteins;
the higher early antipeptide response to SWAP in vaccinated
chimpanzees is promising in this context. We are currently test-
ing the smoke screen hypothesis in mice and baboons exposed
to the RA vaccine.
Peripheral blood mononuclear cells (PBMC) from patients
with acute disease are strongly responsive to schistosome anti-
gens, whereas PBMC from persons with the chronic intestinal
form are invariably less reactive [42]. Whether the pattern of
reduced cellular reactivity is repeated for antibody responses is
less clear. In the current study, specific chimpanzee IgM levels to
all antigens declined during PC weeks 10–20, regardless of the
vaccinated or control status of the animals. The IgG responses
to 0–3-hRAP and KLHg also declined in parallel with IgM,
whereas IgG responses to SLAP, SWAP, SEAs, and ESPs re-
mained elevated until the end of the study. This drop in specific
IgM levels could reflect the progression from a primary to a
secondary immune response and involve isotype switching. The
absence of restimulation by incoming larvae might be another
factor influencing the decline in IgM responses to both larval
preparations after challenge, but the cross-reactivity seen with
egg antigens makes this unlikely. Finally, since much of the IgM
is directed against glycan epitopes, decreasing levels might simply
indicate a failure to establish memory for carbohydrate antigens.
However, the production of IgG to glycan epitopes reveals some
degree of isotype switching, implying major histocompatibility
complex type II restriction and T cell help. Conversely, the pro-
duction in some chimpanzees of IgM but not IgG to the defined
glycan epitopes LDN and LDNF [31, 43, 44] suggests a T cell–
independent response in those animals. Presumably, certain an-
tigens released by eggs or larvae behave in this way because they
are largely polysaccharide or bear repeating glycan epitopes on
a peptide carrier backbone that lacks T cell epitopes. The fact
that IgM against LDN and LDNF was induced by vaccination,
but that IgG did not appear before patency, argues for the pres-
ence of these carbohydrate structures on both larval and egg
antigens, but on different protein backbones. The low overall
response to LeX in chimpanzees is consistent with earlier obser-
vations in human patients, unlike rhesus monkeys, mice, and
hamsters [45–47]. Nevertheless, glycan epitopes including LeX
may play an important role in down-modulating the cellular
immune response [48, 49].
IgG antibodies directed against the protein backbone of lar-
val, adult worm, and egg antigens rose steadily during the
chronic phase. Unfortunately, we could not analyze IgG isotype
responses in the chimpanzees and correlate them with data from
human patients [20], because monoclonal antibodies against
human IgG2 and IgG4 react with the same chimpanzee im-
munoglobulin fraction [50] (authors’ unpublished data), which
suggests that chimpanzees have only 3 IgG subclasses. Higher
amounts of peptide-specific IgG against SEAs and SmE16 were
present in the controls than in the vaccinated chimpanzees,
which could be due to the difference in egg production between
groups. Of note, IgE and IgA antibodies have been postulated
to participate in protective immunity in humans [7–9, 51]. Un-
fortunately, owing to limitations of material, we could not do
assays for parasite-specific IgA or IgE.
Many of the data presented here may have direct implications
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for human patients, for whom there is negligible longitudinal
information on the development of antibody responses during
the acute and chronic stages of a schistosome infection. Our
results in control chimpanzees most likely mirror the events that
occur after schistosome infection of persons living in endemic
areas (in the absence of chemotherapeutic intervention) and
therefore provide a vital and detailed reference for the interpre-
tation of data from epidemiologic field studies. There is a need
to expand our knowledge of the structure and diversity of schis-
tosome larval and egg glycans if we are to understand fully the
complex interactions of the schistosome parasite with the host’s
immune system and its ability to subvert protective mechanisms.
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